Abstract 200P
Background
Understanding the complex biology of metastatic tumors is critical for advancing cancer biology research and improving therapeutic interventions. To address this challenge, we have developed a novel multi-organ-on-chip (Multi-OOC) platform designed to unravel the intricacies of breast to bone (B2B) metastatic tumor growth. This innovative platform integrates organ-specific tissue models fluidically interconnected to mimic the dynamic interactions between primary tumor and distant organ during metastasis. By replicating the physiological microenvironments of various target organs, our model provides a unique opportunity to investigate the entire metastatic cascade, from tumor cell dissemination, circulating tumor cells (CTCs) survival under flow and colonization. In order to support real-time monitoring of cellular infiltration and response to therapeutic agents in a multi-organ context optically transparent OOC device has been developed, compatible with the optical microscope observation.
Methods
A breast cancer cell laden hydrogel has been developed by using MDA-MB-231 cells with and without endothelial cells (HUVEC), forming the capillary network. A computational fluid dynamic simulation was done to set up the proper capillary velocity and induced shear stresses. In a second chamber, a bone tissue model was developed as metastasis target: different ratio of hydroxyapatite (HA) has been included in a polymeric matrix to introduce a bone like mineral phase. Tumor cell infiltration and CTC survival rate have been monitored using different fluid-dynamic conditions and HA content.
Results
A multicompartmental OOC has been developed and successfully validated. The 3D breast cancer model displayed long term (2 months) survival in vitro in dynamic conditions, and a cells cytoskeleton reorganization was highlighted. The CTCs survival was shown correlated to the shear stresses induced by the fluid flow into the Multi-OOC. Different levels of CTCs infiltration in the mineralized matrix hosted in the metastatic OOC chamber were observed.
Conclusions
This platform holds great promise for accelerating the development of targeted therapies and personalized treatment strategies, ultimately advancing our understanding of metastatic cancer biology.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Aiello, S. Scaglione: Financial Interests, Personal, Member of Board of Directors: React4life. All other authors have declared no conflicts of interest.
Resources from the same session
60P - Adaptive NK cells as a therapeutic option for childhood leukaemia
Presenter: Zoya Eskandarian
Session: Poster Display
61P - Unlocking the Power of Natural Killer Cells: Precision Selection with Cutting-Edge Microfluidics
Presenter: Neelima KC
Session: Poster Display
63TiP - A phase I study of tumor-infiltrating lymphocytes (TILs) in advanced solid tumors used an optimized regimen: MIZAR trial
Presenter: Qing Xu
Session: Poster Display
68P - Real-world (rw) outcomes in patients (pts) with metastatic (m) NSCLC and STK11, KEAP1 and/or KRAS mutations (mut) receiving PD-(L)1-based treatment (tx): CORRELATE
Presenter: Solange Peters
Session: Poster Display
70P - LIST (Lung Initiative on Sequence Therapy), a real-world study of nivolumab for advanced NSCLC in France: first effectiveness, safety, and IO-rechallenge results
Presenter: Benoît GODBERT
Session: Poster Display
72P - Camrelizumab plus apatinib after chemoradiotherapy in unresectable stage III non-small-cell lung cancer?A multi-center, single-arm, phase 2 study
Presenter: Hui Zhouguang
Session: Poster Display
74P - A single-center, Phase II study of surufatinib combined with toripalimab, pemetrexed(A), and platinum (P) in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC)
Presenter: Wen Feng Fang
Session: Poster Display
75P - Patient-reported outcomes (PROs) of cemiplimab + chemotherapy in advanced non-small cell lung cancer (NSCLC): EMPOWER-lung 3 liver metastases subpopulation
Presenter: Ana Baramidze
Session: Poster Display